Survival outcomes in this observational study are similar to those reported in the landmark RCTs in HER2-positive early breast cancer.4,6,10 However, in contrast to some clinical trials, only two-thirds of patients initiating trastuzumab in our study completed the standard 12-month course. Here, ERBB2 is linked to breast cancer.